Table 1 Comparison of clinical features between LUAD patients with low and high ESCO2 levels in TCGA database
From: ESCO2 promotes lung adenocarcinoma progression by regulating hnRNPA1 acetylation
Clinical character# | Clinical groups | ESCO2 | x2 | p value | |
|---|---|---|---|---|---|
High (n = 155) (%) | -Low (n = 155) (%) | ||||
Age (years) | ≤ 60 | 54 (34.8) | 41 (26.5) | 2.611 | 0.106 |
>  60 | 95 (61.3) | 108 (69.7) | |||
Gender*** | Male | 91 (58.7) | 59 (38.1) | 13.23 | < 0.001 |
Female | 64 (41.3) | 96 (61.9) | |||
ALK Translocation | No | 54 (34.8) | 71 (45.8) | 0.377 | 0.539 |
Yes | 12 (7.7) | 12 (7.7) | |||
pT status*** | T1 T2 ~ T4 | 37 (23.9) | 66 (42.6) | 12.27 | < 0.001 |
117 (75.5) | 88 (56.8) | ||||
pN status** | N0 | 88 (56.8) | 110 (71.0) | 8.771 | 0.003 |
N1 ~ N2 | 66 (42.6) | 40 (25.8) | |||
pM status* | M0 | 106 (68.4) | 101 (65.2) | 4.026 | 0.045 |
M1 | 13 (8.4) | 4 (2.6) | |||
Recurred/Progressed** | No | 62 (40.0) | 88 (56.8) | 8.317 | 0.004 |
Yes | 67 (43.2) | 46 (29.7) | |||
Clinical Stage** | Stage I ~ IIA | 83 (53.5) | 106 (68.4) | 7.761 | 0.005 |
Stage IIB ~ IV | 70 (45.2) | 46 (29.7) | |||